Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 49Breast 44Endocrine 25CNS 23Gastrointestinal 22NET 18Lymphoid 16Head & Neck 10Dermatologic 9Tumor-Agnostic 8Thoracic 8Sarcoma 8Other hematologic neoplasm 8Gynecologic 8Other solid neoplasm 4Plasma cell 3Other 1Myeloid 1

Conditions

Mastocytosis, Systemic 1

Interventions

fludarabine phosphate 113Cyclophosphamide 97Whole-Body Irradiation 82Mycophenolic Acid 79fludarabine 74Tacrolimus 69Busulfan 68Azacitidine 62Peripheral Blood Stem Cell Transplantation 59Melphalan 48Cytarabine 48Antilymphocyte Serum 47Methotrexate 45Cyclosporine 45Filgrastim 39Imatinib Mesylate 37Granulocyte Colony-Stimulating Factor 37Decitabine 35nilotinib 34thymoglobulin 31ruxolitinib 29Thiotepa 27Stem Cell Transplantation 23Clofarabine 22Alemtuzumab 21Rituximab 19Dasatinib 19Cord Blood Stem Cell Transplantation 19sargramostim 17Sirolimus 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Everolimus × Myeloid × Clear all
NCT00449748 2025-05-01

Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis

M.D. Anderson Cancer Center

Phase 2 Completed
10 enrolled 4 charts
Myeloid

Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡